BSE Live
Mar 20, 16:01Prev. Close
38.13
Open Price
37.37
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 20, 15:15Prev. Close
38.12
Open Price
0.00
Bid Price (Qty.)
41.30 (35)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Take Solutions (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 1.69 | 1.18 | 1.14 | 1.44 | 1.52 | |
| Diluted EPS (Rs.) | 1.69 | 1.17 | 1.14 | 1.43 | 1.50 | |
| Cash EPS (Rs.) | 1.80 | 1.23 | 1.08 | 1.14 | 1.53 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 52.93 | 51.54 | 52.02 | 38.88 | 26.55 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 52.93 | 51.54 | 52.02 | 38.88 | 26.55 | |
| Dividend / Share(Rs.) | 0.00 | 1.00 | 1.60 | 1.00 | 1.00 | |
| Revenue from Operations/Share (Rs.) | 0.17 | 1.48 | 0.16 | 1.41 | 1.96 | |
| PBDIT/Share (Rs.) | 1.87 | 1.37 | 1.11 | 1.37 | 1.72 | |
| PBIT/Share (Rs.) | 1.75 | 1.32 | 1.05 | 1.31 | 1.70 | |
| PBT/Share (Rs.) | 1.72 | 1.32 | 1.00 | 1.09 | 1.69 | |
| Net Profit/Share (Rs.) | 1.69 | 1.18 | 1.03 | 1.08 | 1.52 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 1,122.18 | 92.49 | 671.69 | 97.09 | 87.55 | |
| PBIT Margin (%) | 1,051.54 | 88.84 | 638.96 | 92.86 | 86.76 | |
| PBT Margin (%) | 1,034.30 | 88.84 | 604.75 | 77.35 | 85.95 | |
| Net Profit Margin (%) | 1,011.27 | 79.21 | 625.59 | 76.53 | 77.33 | |
| Return on Networth / Equity (%) | 3.18 | 2.28 | 1.98 | 2.78 | 5.71 | |
| Return on Capital Employed (%) | 3.28 | 2.55 | 1.97 | 2.78 | 5.71 | |
| Return on Assets (%) | 3.14 | 2.24 | 1.96 | 2.70 | 4.40 | |
| Total Debt/Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.23 | |
| Asset Turnover Ratio (%) | 0.31 | 2.83 | 0.31 | 3.52 | 5.69 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 58.40 | 23.43 | 64.05 | 9.11 | 0.76 | |
| Quick Ratio (X) | 58.40 | 23.43 | 64.02 | 9.11 | 0.76 | |
| Inventory Turnover Ratio (X) | 98.64 | 686.22 | 13.18 | 785.13 | 481.02 | |
| Dividend Payout Ratio (NP) (%) | 23.72 | 136.06 | 87.35 | 92.38 | 67.14 | |
| Dividend Payout Ratio (CP) (%) | 22.17 | 130.07 | 83.01 | 87.55 | 66.46 | |
| Earnings Retention Ratio (%) | 76.28 | -36.06 | 12.65 | 7.62 | 32.86 | |
| Cash Earnings Retention Ratio (%) | 77.83 | -30.07 | 16.99 | 12.45 | 33.54 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 586.24 | 2,190.32 | 2,265.59 | 1,662.66 | 1,757.23 | |
| EV/Net Operating Revenue (X) | 237.73 | 99.75 | 929.28 | 88.24 | 74.55 | |
| EV/EBITDA (X) | 21.18 | 107.84 | 138.35 | 90.88 | 85.15 | |
| MarketCap/Net Operating Revenue (X) | 238.15 | 100.88 | 991.76 | 89.55 | 72.50 | |
| Retention Ratios (%) | 76.27 | -36.06 | 12.64 | 7.61 | 32.85 | |
| Price/BV (X) | 0.75 | 2.91 | 3.14 | 3.26 | 5.36 | |
| Price/Net Operating Revenue | 238.15 | 100.88 | 991.81 | 89.56 | 72.51 | |
| Earnings Yield | 0.04 | 0.01 | 0.01 | 0.01 | 0.01 |
01.01.2026
14.06.2024
Take Solutions Consolidated March 2024 Net Sales at Rs 13.21 crore, down 64.82% Y-o-Y
22.02.2024
Take Solutions Consolidated December 2023 Net Sales at Rs 16.85 crore, down 68.56% Y-o-Y
09.11.2023
Take Solutions Consolidated September 2023 Net Sales at Rs 18.09 crore, down 59.69% Y-o-Y
14.06.2024
Take Solutions Consolidated March 2024 Net Sales at Rs 13.21 crore, down 64.82% Y-o-Y
22.02.2024
Take Solutions Consolidated December 2023 Net Sales at Rs 16.85 crore, down 68.56% Y-o-Y
09.11.2023
Take Solutions Consolidated September 2023 Net Sales at Rs 18.09 crore, down 59.69% Y-o-Y
16.08.2023
Take Solutions Standalone June 2023 Net Sales at Rs 5.42 crore, down 59.51% Y-o-Y
22.03.2026
Sell-on-rise market? SBI Securities sees Nifty under pressure, picks two stocks for the week ahead
20.03.2026
Eris Lifesciences, Natco Pharma to launch generic Ozempic at 90% cheaper price
20.03.2026
Semaglutide’s patent expires today. What does it mean for patients, pharma players and Novo Nordisk?
20.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth